Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CPI-613, the Company's lead Altered Energy Metabolism Directed (AEMD) drug candidate, for the treatment of myelodysplastic syndrome (MDS).
MDS is a form of cancer that occurs when the blood-forming cells in the bone marrow are damaged, which leads to low numbers of one or more type of blood cells. In about one-third of MDS cases, the disease progresses to a rapidly growing cancer of bone marrow cells called acute myeloid leukemia (AML). Currently no cure for MDS exists for patients with this life-threatening disease.
Robert Rodriguez, Cornerstone's President and Chief Operating Officer, said, "Approximately 15,000 people are diagnosed with MDS in the United States each year. Treatment options for MDS patients are limited, especially for patients with relapsed or refractory disease, and are often associated with myelosuppressive side effects. We are encouraged by the lack of myelosuppression, good tolerability and signals of activity that were observed in MDS patients in the Phase I trial. We look forward to expanding our experience with CPI-613 as a monotherapy in the treatment of relapsed / refractory MDS patients in the recently launched Phase II MDS clinical trial as well as the possibility of establishing CPI-613 as an alternative treatment option for this rare and devastating disease."
Orphan drug designation is granted by the FDA to therapeutics intended to treat rare diseases that affect fewer than 200,000 individuals in the United States. The designation entitles Cornerstone Pharmaceuticals to seven years of U.S. marketing exclusivity for CPI-613 upon regulatory approval, as well as an opportunity to apply for grant funding from the U.S. government to defray costs of clinical trial expenses, tax credits for clinical research expenses, and a potential waiver of the FDA's application user fee. In addition to MDS, Cornerstone Pharmaceuticals has previously received orphan drug designation for the use of CPI-613 in the treatments of AML and pancreatic carcinoma.
CPI-613 induces cancer-specific inhibition of pyruvate dehydrogenase (PDH) and alpha ketoglutarate dehydrogenase (KGDH), key mitochondrial enzymes involved in cancer cell metabolism. Disruption of PDH and KGDH function leads to catastrophic disruption of tumor mitochondrial metabolism. As a result, tumor cells are starved of energy and biosynthetic intermediates, culminating in cell death. CPI-613 is currently being evaluated in Phase I, I/II and Phase II trials in hematologic malignancies and solid tumors. The results from the Phase I single agent trial were presented at the 2013 American Society for Clinical Oncology (ASCO) Annual Meeting and hand-selected for inclusion in the Best of ASCO 2013 educational series.
CPI-613 is the lead drug candidate from Cornerstone's proprietary AEMD platform. Cornerstone's AEMD drug platform disrupts biochemical alterations in the conversion of glucose to energy that occur in many types of cancer cells. These essential "bioenergetic" differences are linked to critical pathways, particularly those that support cancer cell growth and development.
 American Cancer Society. “What is myelodysplastic syndrome?” Last accessed October 1, 2013. Available at: http://www.cancer.org/cancer/myelodysplasticsyndrome/detailedguide/myelodysplastic-syndromes-what-is-m-d-s
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Blood / Hematology category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Pharmaceuticals, Cornerstone. "Cornerstone pharmaceuticals receives FDA orphan drug designation of CPI-613 for treatment of myelodysplastic syndrome." Medical News Today. MediLexicon, Intl., 7 Oct. 2013. Web.
8 Dec. 2013. <http://www.medicalnewstoday.com/releases/267045>
Pharmaceuticals, C. (2013, October 7). "Cornerstone pharmaceuticals receives FDA orphan drug designation of CPI-613 for treatment of myelodysplastic syndrome." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/267045.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.